Show simple item record

dc.contributor.authorUl Ain Javed, Qurrat
dc.contributor.authorAli Syed, Muhammad
dc.contributor.authorArshad, Rabia
dc.contributor.authorRahdar, Abbas
dc.contributor.authorIrfan, Muhammad
dc.contributor.authorAtif Raza, Syed
dc.contributor.authorShahnaz, Gul
dc.contributor.authorHanif, Sana
dc.contributor.authorDíez Pascual, Ana María 
dc.date.accessioned2023-01-10T07:55:21Z
dc.date.available2023-01-10T07:55:21Z
dc.date.issued2022-04-07
dc.identifier.bibliographicCitationPharmaceutics, 2022, v. 14, n. 4, p. 807en
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10017/55098en
dc.description.abstractThe aim of the projected study was to design and develop a novel strategy for evaluating the mucoadhesive potential of polymeric tablets of dexamethasone (DXM) for local delivery against wounds. Therefore, formulations (Q1-Q7) were synthesized via direct compression method by varying the concentrations of polymers, i.e., ethyl cellulose (EC) and agar extract (AG). Moreover, the mucoadhesive polymeric tablets were characterized via physicochemical, in vitro, ex vivo and in vivo experiments. However, physicochemical characteristics such as FTIR showed no interaction with different polymeric combination. Surface pH of all formulations was normal to slightly alkaline. Highest hydration of up to 6.22% and swelling index was comprehended with maximum concentration of AG (50% of total tablet weight). Whereas, ex vivo and in vivo residence time and mucoadhesion were attributed to the increased concentrations of polymers. Moreover, Q7, (optimized formulation), containing 10% of EC and 40% of AG, exhibited maximum release of DXM (100%) over 8 h, along with sufficient mucoadhesive strength up to 11.73 g, following first-order kinetics having r(2) value of 0.9778. Hemostatic effects and epithelialization for triggering and promoting wound healing were highly pronounced in cases of Q7. Furthermore, in vivo residence time was 7.84 h followed by salivary drug concentration (4.2 mu g/mL). However, mucoadhesive buccal tablets showed stability for 6 months, thus following the standardization (ICH-Iva) stability zone. In summary, DXM mucoadhesive tablets seem to be an ideal candidate for eradication of wound infections via local targeted delivery.en
dc.description.sponsorshipA
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectdexamethasoneen
dc.subjecthemostaticen
dc.subjectwound healingen
dc.subjectsalivary pharmacokineticen
dc.subjectmucoadhesive buccal tableten
dc.subjectin vitro-in vivoen
dc.subjectvolunteer studyen
dc.titleEvaluation and Optimization of Prolonged Release Mucoadhesive Tablets of Dexamethasone for Wound Healing: In Vitro-In Vivo Profiling in Healthy Volunteersen
dc.typeinfo:eu-repo/semantics/articleen
dc.subject.ecienciaQuímicaes_ES
dc.subject.ecienciaChemistryen
dc.contributor.affiliationUniversidad de Alcalá. Departamento de Química Analítica, Química Física e Ingeniería Químicaes_ES
dc.date.updated2023-01-10T07:54:51Z
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics14040807en
dc.relation.projectIDinfo:eu-repo/grantAgreement/CAM/Estímulo a la Excelencia para Profesores Universitarios Permanentes/EPU-INV%2F2020%2F012/ES/es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.identifier.uxxiAR/0000041580en
dc.identifier.publicationtitlePharmaceuticsen
dc.identifier.publicationvolume14
dc.identifier.publicationissue4
dc.identifier.publicationfirstpage807


Files in this item

Thumbnail

This item appears in the following Collection(s)

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Este ítem está sujeto a una licencia Creative Commons.